Brentuximab Vedotin for Stage III or IV Hodgkin's Lymphoma

Affiliations

¹ British Columbia Cancer Centre for Lymphoid Cancer, Vancouver, BC, Canada jconnors@bccancer.bc.ca
² University of Manchester, Manchester, United Kingdom

Comment

Joseph M Connors et al. N Engl J Med. 2018.

. 2018 Apr 19;378(16):1560-1561.

doi: 10.1056/NEJMc1802363.

¹ British Columbia Cancer Centre for Lymphoid Cancer, Vancouver, BC, Canada jconnors@bccancer.bc.ca
² University of Manchester, Manchester, United Kingdom

No abstract available

Comment on

Brentuximab Vedotin for Stage III or IV Hodgkin’s Lymphoma.
Hilal T. Hilal T. N Engl J Med. 2018 Apr 19;378(16):1558-9. doi: 10.1056/NEJMc1802363. N Engl J Med. 2018. PMID: 29671464 No abstract available.
Brentuximab Vedotin for Stage III or IV Hodgkin’s Lymphoma.
Greer JP. Greer JP. N Engl J Med. 2018 Apr 19;378(16):1559. doi: 10.1056/NEJMc1802363. N Engl J Med. 2018. PMID: 29671465 No abstract available.
Brentuximab Vedotin for Stage III or IV Hodgkin’s Lymphoma.
Crump M. Crump M. N Engl J Med. 2018 Apr 19;378(16):1559-60. doi: 10.1056/NEJMc1802363. N Engl J Med. 2018. PMID: 29671466 No abstract available.
Brentuximab Vedotin for Stage III or IV Hodgkin’s Lymphoma.
Canellos GP, LaCasce AS. Canellos GP, et al. N Engl J Med. 2018 Apr 19;378(16):1560. doi: 10.1056/NEJMc1802363. N Engl J Med. 2018. PMID: 29671468 No abstract available.